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           When an immune response is triggered by mi-
crobial pathogens, the innate immune system 
directs T lymphocytes to achieve appropriate 
eff  ector function from diverse pathways to pro-
tect the host against destructive invasion. How-
ever, in some cases, inappropriate T eff  ector cells 
that are unable to control microbial infections 
are induced and expanded, thereby allowing 
pathogens to persist in the host. For example, the 
balance between Th1 and Th2 responses to an 
infectious agent may determine the outcome of 
immunoprotection versus immunopathology 
(  1  ). IL-17  –  producing Th17 cells, which are a 
distinct subset of CD4  +   T cells, comprise another 
T eff  ector cell type that is apparently involved 
in infl  ammatory tissue damage, leading to the 
pathogenesis of various autoimmune diseases (  2  –
  10  ). Furthermore, Th17 also appears to play a 
role in protection against extracellular bacterial 
or fungal diseases (  11  –  13  ). The production of 
IL-17 has been reported during HIV infection in 
humans (  14  –  17  ), and herpes simplex virus (  18  ) 
and respiratory syncytial virus infections (  19  ) in 
rodents. However, the induction of Th17 cells 
during persistent viral infection, and their poten-
tial roles in the establishment of viral persistence 
and the pathogenesis of chronic viral infection  –
  associated diseases remain undefi  ned. 
  During viral infection, most CD4  +   T cells 
isolated from the virus target organ belong to the 
Th1 type (  1, 20  ). Th1 cytokines, such as IFN-    , 
display strong antiviral function and antagonize 
the development of Th17 cells (  2, 4  ). For exam-
ple, in simian immunodefi  ciency virus  –  infected 
rhesus macaques, Th17 cells are markedly de-
pleted (  21  ). The induction of type I IFNs and 
their downstream signaling pathways in response 
to viral infection may constrain Th17 develop-
ment (  22, 23  ). In opposition to this protective 
strategy, a virus may be able to evade antiviral 
types I and II IFN responses (  24  ), facilitating its 
persistence in the host by inducing elevated levels 
of IL-17  –  producing CD4  +   and/or CD8  +   T cells 
(  25  ). However, the potential role of Th17 cells in 
the pathogenesis of virus-induced chronic in-
fl  ammatory diseases is virtually unknown. Th17 
cells, via their cytokine IL-17, play a pivotal role 
in mediating diff  erent types of tissue infl  amma-
tion and destruction in chronic toxoplasmic en-
cephalitis (  26  ) and psoriasis (  27  ). Therefore, it is 
conceivable that persistent chronic viral infection 
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  Persistent viral infection and its associated chronic diseases are a global health concern. 
Interleukin (IL) 17  –  producing Th17 cells have been implicated in the pathogenesis of 
various autoimmune diseases, and in protection from bacterial or fungal infection. However, 
the role of Th17 cells in persistent viral infection remains unknown. We report that Th17 
cells preferentially develop in vitro and in vivo in an IL-6  –  dependent manner after Theiler  ’  s 
murine encephalomyelitis virus infection. Th17 cells promote persistent viral infection and 
induce the pathogenesis of chronic demyelinating disease. IL-17 up-regulates antiapoptotic 
molecules and, consequently, increases persistent infection by enhancing the survival of 
virus-infected cells and blocking target cell destruction by cytotoxic T cells. Neutralization 
of IL-17 augments virus clearance by eliminating virus-infected cells and boosting lytic 
function by cytotoxic T cells, leading to the prevention of disease development. Thus, these 
results indicate a novel pathogenic role of Th17 cells via IL-17 in persistent viral infection 
and its associated chronic infl  ammatory diseases. 
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pletely abrogated Th17 development (  Fig. 1 D  ). These re-
sults collectively indicate that IL-6 produced by virus-infected 
DCs likely drives Th17 cell diff  erentiation. To directly 
address the eff  ect of viral infection on virus-specifi  c Th17 
development, we used TCR transgenic SJL/J (SJL) mice 
(backcross generation N14) that recognize TMEV capsid 
protein 2 epitope (VP2  74-86  ) (unpublished data). Naive VP2-
TCR transgenic T cells (CD4  +  CD25       CD44  low  ) sorted on a 
MoFlo cytometer (see Materials and methods) were used to 
assess the development of Th17 cells. Again, virus-infected 
SJL BMDCs preferentially supported the diff  erentiation of 
Th17 cells, producing signature cytokines (IL-17 and IL-22) 
and an infl  ammatory cytokine (TNF-    ), whereas those stim-
ulated by BMDCs loaded with VP2  74-86    –   or UV light  –  inacti-
vated TMEV (UV-TMEV) failed to generate Th17 cells 
despite the vigorous development of Th1 cells producing 
IFN-     (  Fig. 1 E  ). Thus, our data clearly demonstrate that vi-
ral infection drives antigen-presenting cells to preferentially 
induce Th17 development in vitro. 
  Elevated levels of Th17 cells in TMEV-infected 
susceptible mice compared with resistant mice 
  To determine whether persistent viral infection fosters virus-
specifi  c Th17 responses in vivo, we analyzed levels of IL-17  –
  producing cells in the CNS of susceptible SJL and resistant 
C57BL/6 (B6) mice at 8 d after TMEV infection. IL-17 pro-
duction by CNS-resident microglia and infi  ltrated  macro-
phages, DCs, granulocytes, B cells, and cytotoxic CD8  +   T 
cells from both mouse strains was either undetectable or negli-
gible (  Fig. 2 A  ).   However, low but detectable levels of IL-17  –
  producing CD4  +   T cells were found in virus-infected SJL 
but not B6 mice (  Fig. 2, A and C  ). To confi  rm these fl  ow 
cytometry results, we assessed mRNA levels of IL-17 and the 
Th17 lineage  –  specifi  c transcription factor ROR    t in sorted 
CD4  +  CD8       , CD4       CD8  +  , and CD4       CD8        CNS-infi  ltrating 
mononuclear cells from TMEV-infected SJL and B6 mice 
(  Fig. 2 B  ). Both IL-17 and ROR    t mRNAs were primarily 
expressed by the CD4  +   T cell fraction of SJL mice compared 
with other SJL cellular fractions (P   <   0.001) or CNS-infi  ltrat-
ing cells from B6 mice (P   <   0.001). These results clearly indi-
cate that CD4  +   T cells are the predominant source of IL-17 in 
the CNS of virus-infected susceptible SJL mice. Th17 cell 
numbers in the CNS of SJL mice were as much as 100-fold 
greater than those of B6 mice (  Fig. 2 C  , bottom). In contrast, 
no diff   erence in the overall number of IFN-      –  producing 
CD4  +   T cells between these strains was found as a result of el-
evated CD4  +   T cell infi  ltration to the CNS in SJL mice (  Fig. 
2 C  , bottom), although the proportion of IFN-      –  producing 
CD4  +   T cells was lower in TMEV-infected SJL mice in com-
parison to B6 mice (  Fig. 2 C  , top). Th17 cells in infected 
SJL mice appear to be viral antigen specifi  c, because similar 
levels of IL-17  –  producing CD4  +   T cells were found after in 
vitro stimulation with anti-CD3/CD28 versus UV-TMEV 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20082030/DC1). Upon restimulation of CNS-infi  ltrating 
cells with UV-TMEV ex vivo, signifi  cantly higher levels of 
might be associated with a polarized Th17 response that 
may further exert a positive or negative feedback loop on 
viral persistence and the pathogenesis of virus-induced 
chronic diseases. 
  In this study, we used the Theiler  ’  s murine encephalomy-
elitis virus (TMEV)  –  induced demyelinating disease model 
system, which displays immune parameters and histopathol-
ogy similar to those of chronic progressive multiple sclerosis 
(  28  –  30  ). TMEV is a natural mouse pathogen belonging 
to the piconavirus family, which includes many important 
pathogens of humans and animals; e.g., poliovirus causes par-
alytic disease in humans, and coxsackievirus results in mild to 
severe myocarditis, encephalitis, and diabetes (  31  ). We inves-
tigated the eff  ects of viral infection on Th17 development in 
vitro and in vivo, the eff  ects of IL-17 neutralization on viral 
persistence in the virus target, the central nervous system 
(CNS), and the subsequent development of chronic demye-
linating disease. In addition, we assessed the role of IL-17 in 
viral infection/replication and antiviral T cell cytotoxic func-
tion. Our results show that viral infection preferentially in-
duces the development of Th17 cells, and in turn, these cells 
uniquely promote viral persistence via IL-17 by inhibiting 
apoptosis of infected cells as well as by desensitizing target cell 
killing by T eff  ector cells, leading to the pathogenesis of asso-
ciated chronic demyelinating disease. 
    RESULTS   
  Preferential induction of Th17 development 
by virus-infected DCs in vitro 
  To examine whether virus-infected antigen-presenting cells 
preferentially drive a Th17 response, purifi  ed CD4  +   T cells 
from OT-II TCR transgenic mice specifi  c for OVA peptide 
323  –  339 (OVA  323-339  ) were stimulated for 4 d with TMEV-
infected BM-derived DCs (BMDCs) in the presence of the 
cognate peptide. Th1/Th17 cell diff  erentiations evoked by 
mock- and virus-infected DCs were compared using intra-
cellular staining of IFN-     and IL-17, respectively (  Fig. 1, 
A and B  ).   The results indicate that Th17 cell development is 
preferentially increased after stimulation with virus-infected 
DCs in an infection-dose  –  dependent manner (  Fig. 1 A  ). In-
terestingly, paraformaldehyde-fi  xed virus-infected DCs failed 
to induce polarized Th17 development (  Fig. 1 B  ), suggesting 
that the skewed Th17 development is dependent on soluble 
factors from virus-infected DCs. To identify cytokines in-
volved in enhanced Th17 development, key Th1/Th17 cell 
diff  erentiation  –  associated cytokines (IL-6, IL-12, and IL-23) 
produced in the supernatants of virus-infected DCs were as-
sessed (  Fig. 1 C  ). Notably, virus-infected DCs produced 
higher levels of IL-6 and IL-12p40 compared with mock-
  infected DCs, suggesting their possible role in elevated Th17 
cell diff  erentiation. Addition of IL-6 to the co-cultures of 
uninfected DCs and OT-II T cells in the presence of cognate 
peptide promoted Th17 development (  Fig. 1 D  ), confi  rming 
the potential role of IL-6 in Th17 elevation. In addition, 
treatment of the co-cultures consisting of OT-II T cells and 
virus-infected DCs with neutralizing antibodies to IL-6 com-JEM VOL. 206, February 16, 2009 
ARTICLE
315
during viral infection, but not in B6 mice (  Fig. 2 E  ), strongly 
suggesting that this cytokine plays a key role in Th17 develop-
ment and expansion. Collectively, these observations indicate 
that viral infection in susceptible SJL mice results in the prefer-
ential development of Th17 responses, along with low levels 
of Th1 responses as compared with resistant B6 mice. 
IL-17 and lower levels of IFN-     were detected from SJL ver-
sus B6 mice (  Fig. 2 D  ). This discrepancy between IFN-     lev-
els (  Fig. 2 D  ) and IFN-      –  producing cell numbers (  Fig. 2 C  ) 
may refl  ect diff  erences in cytokine levels produced per cell by 
SJL and B6 mice. It is interesting to note that IL-6 is detectable 
only in the CNS (both brains and spinal cords) of SJL mice 
    Figure 1.         Virus-infected DCs promote Th17 development in vitro.   (A) Flow cytometry of OT-II T cells cultured for 4 d with B6 BMDCs infected with 
varying MOIs in the presence of OVA  323-339  . Intracellular cytokine production was determined after restimulation with PMA plus ionomycin for 6 h. (B) Flow 
cytometry of OT-II T cells cultured for 4 d with TMEV-infected B6 BMDCs (MOI of 10), which were treated with PBS (unfi  xed) or fi  xed with 0.1% paraformalde-
hyde. Plots represent gated CD4  +   T cells. (C) Cytokines produced by B6 BMDCs infected with TMEV (MOI of 10) or stimulated with LPS. **, P   <   0.01 versus mock. 
(D) Flow cytometry of OT-II T cells stimulated with OVA  323-339   in the presence of B6 BMDCs with or without IL-6, or in the presence of TMEV-infected B6 BM-
DCs (MOI of 10) with either isotype or anti  –  IL-6 antibodies. Plots represent gated CD4  +   T cells. (E) Intracellular and extracellular cytokine production by isolated 
naive (CD4  + CD25     CD44 low  ) VP2 transgenic CD4  +   T cells after stimulation with VP2  74-86    –   and UV-TMEV  –  pulsed or TMEV-infected SJL BMDCs. The data are a 
representative of three independent experiments (means   ±   SD are shown in C and E). The numbers in each quadrant represent percentages. UD, undetectable.    316 IL-17 PROMOTES VIRAL PERSISTENCE AND PATHOGENESIS   | Hou et al. 
mice, resulted in persistent infection as well as clinical symp-
toms, whereas no detectable disease development and low vi-
ral persistence were observed in control PBS-treated mice 
(  Fig. 3, A and B  ).   The number of IL-17  –  producing CD4  +   T 
cells in the CNS of LPS-treated mice was increased   >  300-
fold compared with that of control PBS-treated mice (  Fig. 3 C  ). 
In contrast, similar proportions and numbers of IFN-      – 
producing CD4  +   T cells were observed between LPS- and 
  IL-6  –  dependent elevation of Th17 cell numbers in B6 mice 
after TMEV infection in conjunction with LPS treatment 
  To further correlate the observed increase in Th17 develop-
ment with susceptibility to TMEV-induced demyelinating 
disease, we rendered resistant B6 mice susceptible by adminis-
tration of the Gram-negative endotoxin LPS, as demonstrated 
in our earlier work (  32  ). Intraperitoneal injection of LPS, con-
comitant with intracerebral TMEV infection in resistant B6 
    Figure 2.         Th17 development is elevated in virus-infected susceptible SJL mice.   (A) Intracellular IL-17 analysis of CNS mononuclear cells from 
virus-infected SJL and B6 mice (  n   = 3) after stimulation with PMA plus ionomycin. The number in each plot shows the proportion of IL-17  –  producing 
cells. (B) Induction of IL-17 and ROR    t mRNAs in isolated CD4  + CD8     ,  CD4     CD8 +  , and CD4      CD8       CNS mononuclear cells relative to GAPDH mRNA. Isola-
tion of cell populations from SJL and B6 mice (  n   = 6) at 8 d after TMEV infection was achieved using a MoFlo cytometer. ***, P   <   0.001 for SJL versus B6 
mice. (C) Flow cytometry of SJL and B6 CNS-infi  ltrating cells from infected mice (  n   = 3), followed by stimulation with PMA plus ionomycin. Each plot is 
gated on CD4  +   T cells (percentages are shown). The bar graphs depict cell numbers of cytokine-secreting CNS-infi  ltrated CD4  +   T cells. **, P   <   0.01 for SJL 
versus B6 mice. (D) ELISA of IL-17 and IFN-     produced by CNS-infi  ltrated cells isolated from mice (  n   = 3) at 8 d after TMEV infection after stimulation 
with different doses of UV-TMEV. **, P   <   0.01 for SJL versus B6 mice. (E) IL-6 levels in the CNS of SJL and B6 mice (  n   = 3) were measured by ELISA. **, P   <   
0.01 for SJL versus B6 mice. Data presented in A and C  –  E are representative of three independent experiments, and the results in B represent one out of 
two independent experiments (means   ±   SD are shown in B  –  E). UD, undetectable.     JEM VOL. 206, February 16, 2009 
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chemokines are known to be associated with IL-17 signaling 
pathways (  10  ). These results are consistent with in vitro obser-
vations that the treatment of BMDCs with LPS signifi  cantly 
PBS-treated mice. LPS-treated mice exhibited signifi  cantly 
higher levels of IL-6 in particular, as well as CXCL1/KC and 
CCL2/MCP-1 in the brain (  Fig. 3 D  ). These cytokines and 
    Figure 3.         Virus infection in conjunction with bacterial endotoxin administration promotes Th17 development in resistant B6 mice via elevated 
IL-6.   (A) B6 mice were infected with TMEV in conjunction with intraperitoneal injection of PBS (  n   = 10) or LPS (  n   = 10), and the development of demyelinat-
ing disease was monitored. One representative out of three independent experiments is shown. (B) Levels of infectious virus in the CNS were quantifi  ed 8 and 
21 d after TMEV infection in PBS- or LPS-treated B6 mice. *, P   <   0.05 between LPS- and PBS-treated groups. (C) CNS-infi  ltrating cells obtained at 8 d after 
TMEV infection from PBS- or LPS-treated mice were restimulated with PMA plus ionomycin. Plots represent gated CD4  +   T cells (percentages are shown), and 
the graph shows numbers of cytokine-secreting CD4  +   T cells. **, P   <   0.01 between LPS- and PBS-treated groups. (D) Levels of IL-6, KC, and MCP-1 in brains 
were measured using ELISA 8 d after TMEV infection in PBS- or LPS-treated mice. **, P   <   0.01 between LPS- and PBS-treated groups. (E) IFN-     and IL-17 levels 
produced by splenocytes isolated from PBS- (TMEV/PBS) or LPS-treated (TMEV/LPS) B6 mice 8 d after mock or TMEV infection were assessed using ELISA after 
restimulation with mixed CD4 epitopes, UV-TMEV, or mixed CD8 epitopes. **, P   <   0.01 between LPS- and PBS-treated groups. (F) CNS mononuclear cells iso-
lated from LPS-treated WT or IL-6 KO mice at 8 d after TMEV infection were restimulated with PMA plus ionomycin. All plots show gated CD4  +   T cells (per-
centages are shown), and the bar graphs represent numbers of cytokine-producing CD4  +   T cells. **, P   <   0.01 between WT and IL-6 KO groups. (G) Viral titers in 
the CNS of WT and IL-6 KO mice 8 and 21 d after infection are shown. *, P   <   0.05 between WT and IL-6 KO groups. Results in B  –  G represent values from 
pooled CNS or spleens of two mice per group and are representative examples of three separate experiments (means   ±   SD are shown). UD, undetectable.    318 IL-17 PROMOTES VIRAL PERSISTENCE AND PATHOGENESIS   | Hou et al. 
enhances the induction of Th17 cells as compared with treat-
ment with PBS (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20082030/DC1). Thus, LPS treatment 
appears to be a prerequisite for Th17 elevation to the patho-
genic threshold in TMEV-infected resistant B6 mice, in con-
trast to TMEV-infected susceptible SJL mice that generate a 
high level of Th17 cells. Th17 cells found in LPS-treated mice 
appear to represent virus-specifi  c CD4  +   T cells, because IL-17 
production by peripheral splenocytes was observed in response 
to MHC class II  –  restricted viral epitopes or UV-TMEV, but 
not MHC class I  –  restricted epitopes (  Fig. 3 E  ). In contrast, 
levels of viral antigen  –  specifi  c IFN-     responses were similar in 
both the virus-infected PBS- and LPS-treated groups. Because 
it was previously reported that Th1 responses antagonize Th17 
development (  2, 4  ), fi  nding similar levels of Th1 cells in both 
groups of TMEV-infected mice was unexpected. To further 
determine the role of IL-6 in the increased generation of Th17 
cells in virus-infected mice, we compared levels of Th17 cells 
in virus-infected LPS-treated WT and IL-6 KO B6 mice (  Fig. 3, 
F and G  ). Although similar levels of IFN-      –  producing CD4  +   
T cells were observed in the CNS of virus-infected WT and 
IL-6 KO mice, the development of Th17 cells in the CNS was 
abrogated in IL-6 KO mice (  Fig. 3 F  ). In addition, viral titers 
in the CNS of LPS-treated IL-6 KO mice were signifi  cantly 
lower at days 8 and 21 after TMEV infection compared with 
those of LPS-treated WT mice (  Fig. 3 G  ). Collectively, these 
results clearly demonstrate that both viral persistence and 
the development of TMEV-induced demyelinating disease in 
LPS-treated B6 mice strongly correlate with elevated Th17 
cell levels in the CNS in an IL-6  –  dependent manner. 
  Treatment with antibodies to IL-17 inhibits viral persistence 
and disease development 
  Recent reports indicate that Th17 cells and their cytokine 
IL-17 play a pivotal role in tissue infl  ammation and damage, 
causing CNS demyelination in experimental autoimmune en-
cephalomyelitis and perhaps also in human multiple sclerosis 
(  4, 11  ). To determine whether this T cell type is also involved 
in the establishment of viral persistence and the consequent 
pathogenesis of chronic demyelinating disease, either neutraliz-
ing anti  –  IL-17 antibodies or isotype control antibodies were ad-
ministered to LPS-treated B6 mice at days 0, 7, and 14 relative 
to TMEV infection (  Fig. 4, A  –  F  ).   Treatment with anti  –  IL-17 
antibody reduced serum IL-17 to nearly undetectable levels 
during acute viral infection (8 d after infection) compared with 
treatment with isotype antibody, indicating the eff  ectiveness 
of neutralizing antibodies (Fig. S3 A, available at http://www
.jem.org/cgi/content/full/jem.20082030/DC1). Interestingly, 
IFN-     and IL-17 levels produced by splenocytes in response to 
CD4 epitopes, UV-TMEV, and CD8 epitopes in the control 
group treated with isotype antibodies were comparable with 
mice treated with anti  –  IL-17 antibody (  Fig. 4 A  ), suggesting 
that anti  –  IL-17 antibody treatment neutralizes IL-17 without 
eliminating Th17 cells. However, cellular infi  ltration (CD45  hi   
leukocytes and CD45  hi  CD11b  +   macrophages) to the CNS was 
decreased by more than twofold at day 8 after infection. Levels 
of Th17-associated IL-6, KC, and MCP-1 were also lower in 
the CNS of anti  –  IL-17 antibody  –  treated mice than in isotype 
antibody  –  treated mice (  Fig. 4, B and C  ). Despite low levels 
of leukocyte infi  ltration in anti  –  IL-17 antibody  –  treated mice, 
IFN-     and IL-17 production by CD4  +   T cells (  Fig. 4 D  ) and 
IFN-     production by CD8  +   T cells (Fig. S3 B) in the CNS 
were uncompromised. We further analyzed whether TMEV 
persists and induces chronic demyelinating disease in these 
antibody-treated mice. Viral persistence in the CNS was 
signifi  cantly lower at days 8 and 21 after infection in the anti  – 
IL-17  –  treated group versus the control antibody  –  treated group 
(  Fig. 4 E   and Fig. S4 C). Furthermore, drastic reductions (P   <   
0.01) in the incidence and severity of demyelinating disease 
were observed in the anti  –  IL-17  –  treated group compared with 
control groups of LPS-treated B6 (  Fig. 4 F  ) and susceptible SJL 
mice (  Fig. 4 G  ). Histological examinations of these anti  –  IL-17 
antibody  –  treated groups displayed very little cellular infi  ltration 
and demyelination in spinal cords, in contrast to extensive de-
myelination and cellular infi  ltration in isotype control groups 
(Fig. S4, A and B). Thus, the elimination of IL-17 function 
from virus-infected mice appears to prevent the development 
of demyelinating disease. These results clearly indicate that IL-
17 plays a critical pathogenic role in the establishment of viral 
persistence and pathogenesis of chronic demyelinating disease 
in both temporarily converted genetically resistant B6 mice that 
have become susceptible after LPS treatment (  Fig. 4 F  ) and ge-
netically susceptible SJL mice (  Fig. 4 G  ). 
  IL-17 augments the production of virus-induced IL-6, KC, 
and MCP-1 in permissive cells and protects virus-infected 
cells from apoptosis 
  Because the above observations suggest that IL-17 plays an 
important role in promoting viral persistence and the conse-
quent pathogenesis of infl   ammatory demyelinating disease 
(  Fig. 4  ), we next determined whether or not IL-17 is able to 
directly enhance viral replication and infl  ammatory mediator 
production in permissive cells in vitro (  Fig. 5  ).   As expected, a 
marked reduction of TMEV infection/replication at 24 h af-
ter infection was observed in CD11c  +   BMDCs and primary 
astrocytes pretreated with IFN-     (  Fig. 5, A and C  ). How-
ever, viral infection/replication levels were similar in IL-17  –
  pretreated and untreated cells (  Fig. 5, A and C  ). Despite 
similar levels of viral replication in IL-17  –  pretreated and un-
treated cultures, the production of IL-6, KC, and MCP-1, 
but not IL-12p40, was markedly increased in both IL-17  –
  treated DCs and astrocytes after TMEV infection as com-
pared with control PBS-treated cultures (  Fig. 5, B and D  ). 
Thus, these increases in cytokines and chemokines likely par-
ticipate in further augmenting Th17 development and selec-
tive cellular infi  ltration in the virus target organ, as previously 
shown (  10, 33  ). Furthermore, IL-17 treatment signifi  cantly 
inhibited virus-induced apoptosis of BM cells and primary as-
trocytes but not diff  erentiated BMDCs (  Fig. 5 E  ). Conse-
quently, this IL-17  –  mediated protection against apoptosis 
likely promotes viral persistence in the CNS of virus-infected 
mice, as shown with an increase in virus yield by inhibiting JEM VOL. 206, February 16, 2009 
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    Figure 4.         Treatment of mice with anti  –  IL-17 antibody inhibits viral persistence and the development of demyelinating disease.   (A)  Spleno-
cytes from B6 mice treated with PBS alone, LPS and isotype control antibody (TMEV/LPS/Isotype Abs), or anti  –  IL-17 antibody (TMEV/LPS/    IL-17 Abs) 8 d 
after mock or TMEV infection were restimulated with mixed CD4 epitopes, UV-TMEV, or mixed CD8 epitopes. Cytokines produced in culture supernatants 
were analyzed using ELISA. (B) Flow cytometry of CNS-infi  ltrating cells from these mice at 8 d after infection (percentages are shown). The bar graph 
shows numbers of CNS-infi  ltrating CD45  hi   leukocytes and CD45  hi CD11b +   macrophages. ***, P   <   0.001 for anti  –  IL-17 versus isotype antibody  –  treated 
groups. (C) Levels of IL-6, KC, and MCP-1 in the brains from TMEV-infected B6 mice. **, P   <   0.01; and ***, P   <   0.001 for anti  –  IL-17 versus isotype antibody 
groups. (D) Intracellular cytokine production by CNS-infi  ltrating cells after restimulation with PMA plus ionomycin. All fl  ow plots display gated CD4  +   T 
cells (percentages are shown). The bar graph shows numbers of cytokine-secreting CD4  +   T cells. ***, P   <   0.001 between groups treated with anti  –  IL-17 and 
isotype control antibodies. (E) Viral persistence levels in the CNS 8 and 21 d after infection were determined by plaque assay. *, P   <   0.05; and ***, P   <   0.001 
between anti  –  IL-17 and isotype control groups. Data in A  –  E represent values from a single experiment conducted with pools of spleens or CNS of two 
mice per group (means   ±   SD are shown). Three independent experiments were performed to verify the results. (F and G) B6 mice treated with LPS (F) and 
SJL mice (G) were infected with TMEV in conjunction with isotype control (  n   = 9) or anti  –  IL-17 (  n   = 9) antibody treatment. The effects of anti  –  IL-17 anti-
body treatment on disease development were confi  rmed once by separate experiments (means   ±   SD are shown).     320 IL-17 PROMOTES VIRAL PERSISTENCE AND PATHOGENESIS   | Hou et al. 
compromises the cytotoxic function of CD8  +   T cells, which 
are the key host defense immune mechanism against viral in-
fections. Splenocytes from virus-infected B6 mice at the peak 
of acute infection were pretreated for 24 h or treated simul-
taneously with IL-17 and then assessed for cytolytic func-
tion with a typical short-term (6-h) cytotoxicity assay using 
VP2  121-130    –  loaded EL-4 target cells. Although the specifi  c 
lytic activity of CD8  +   T cells was slightly lower (not statisti-
cally signifi  cant) after pretreatment with IL-17 for 24 h, it re-
mained unchanged after simultaneous treatment with IL-17 
(  Fig. 6 A  ).   Similarly, IL-17 treatment did not signifi  cantly alter 
levels of granzyme B and IFN-     on CD8  +   T cells (  Fig. 6 B  ). 
In contrast, IL-17, but not IL-17F, which has a high degree 
of homology with IL-17 (  35  ), abrogated the slow (60-h) lytic 
reaction (  Fig. 6 C  ) that is prominently mediated by the Fas  –
  FasL pathway (  36  ). This lytic reaction was similarly inhibited 
with IL-17 pretreatment of target cells but not eff  ector cells 
(  Fig. 6 C  ), indicating that IL-17 treatment impedes cytolytic 
function of CD8  +   T cells through signaling on target cells. 
apoptosis of virus-infected cells (  34  ). The failure of IL-17 
treatment to protect BMDCs from apoptosis was not caused 
by the lack of IL-17R expression (Fig. S5 A, available at 
http://www.jem.org/cgi/content/full/jem.20082030/DC1), 
suggesting the involvement of other factors in this protection. 
Interestingly, IL-17  –  mediated protection of BM cells appears 
to be restricted to certain inducers, as apoptosis induced by 
dexamethasone and anti-Fas mAb using the caspase 8 path-
way, but not C2-ceramide and UV irradiation using alterna-
tive pathways, was inhibited (Fig. S5 B). Collectively, these 
fi  ndings indicate that IL-17 augments infl  ammatory responses 
by amplifying the production of proinfl  ammatory cytokines 
and protecting virus-infected cells from apoptotic death. 
  IL-17 inhibits antiviral cytotoxic T cell function in vitro 
  The potential roles of Th17 cells and IL-17 on cytotoxic 
CD8  +   T cell function are unknown. Because treatment of 
mice with anti  –  IL-17 antibodies enhances viral clearance 
from the CNS (  Fig. 4  ), we explored the possibility that IL-17 
    Figure 5.         IL-17 enhances virus-induced production of infl  ammatory cytokines and protects against infection-induced cell apoptosis.  
(A  –  D) B6 BMDCs (A) and astrocytes (C) pretreated with IL-17 or IFN-     for 6 h were infected with TMEV for 24 h. Levels of viral infection were assessed using 
fl  ow cytometry after staining with anti-TMEV antibody or plaque assay with culture supernatants of TMEV-infected cells. The numbers in each quadrant 
represent percentages. UD, undetectable values   <  100 PFU/ml. (C) Histograms represent astrocytes stained with isotype control (red) and anti-TMEV anti-
body (open). Cytokine levels in B6 BMDCs (B) and astrocytes (D) infected with TMEV for 24 h in the presence of PBS or IL-17 were measured using ELISA. 
UD, undetectable values   <  10 pg/ml. *, P   <   0.05; **, P   <   0.01; and ***, P   <   0.001 for IL-17  –   versus PBS-treated cultures. Data in A  –  D are representative of 
four separate experiments (means   ±   SD are shown). (E) TMEV infection  –  induced cell apoptosis was determined using fl  ow cytometry of BM cells (2-d 
culture), BMDCs (5-d culture), and neonatal astrocytes 24 h after coincubation with PBS or IL-17. The number in each histogram represents the percent-
age of Annexin V  high   cells. The graph shows data from three independent experiments. The horizontal bar represents the mean of the group. **, P   <   0.01; 
and ***, P   <   0.001 between IL-17  –   versus PBS-treated cultures.     JEM VOL. 206, February 16, 2009 
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and resident microglia was reduced in anti  –  IL-17 antibody  –
  treated mice compared with isotype antibody  –  treated mice 
(  Fig. 7 B  ). This reduction of antiapoptotic proteins was not 
detectable in antiviral eff  ector CD4  +   and CD8  +   T cells (  Fig. 7 C  ). 
These results indicate that virus-permissive cells from anti  –
  IL-17 antibody  –  treated mice became more susceptible to 
apoptosis. If this is the case, anti  –  IL-17 antibody  –  treated mice 
would be expected to develop low numbers of virus-specifi  c 
CD8  +   T cells corresponding to their limited viral load. To 
examine this possibility, levels of virus-specifi  c CD8  +   T cells 
were assessed using intracellular IFN-     staining after in vitro 
restimulation with dominant and subdominant VP3 epitopes 
(  Fig. 7 D  ). The results indicate that the proportion of virus-
specifi  c CD8  +   T cells in the CNS of anti  –  IL-17 antibody  –
  treated mice is higher yet the overall number is lower compared 
with isotype-treated mice. To further analyze antiviral cyto-
toxic T cell function in antibody-treated mice, in vivo lytic 
responses to target cells loaded with dominant and subdomi-
nant viral epitopes were investigated (  Fig. 7 E  ). TMEV-infected 
susceptible mice treated with anti  –  IL-17 antibody displayed 
signifi  cantly increased elimination of newly introduced viral 
epitope peptide  –  loaded target cells. Collectively, these results 
clearly indicate that anti  –  IL-17 antibody treatment enhances 
the function of antiviral cytotoxic T cells by facilitating the 
removal of virus-infected target cells during viral infection, 
leading to effi   cient viral clearance and, consequently, reduced 
disease development. 
    DISCUSSION   
  We have presented evidence in this paper that virus-infected 
DCs polarize the development of CD4  +   T cells toward the 
Th17 type. During acute viral infection, Th17 cytokine IL-
17 promotes virus-induced infl  ammatory mediators in per-
missive cells to form a pathogenic infl  ammatory milieu, as 
well as to protect cells from both virus- and eff  ector T cell  –
  induced apoptosis, resulting in chronic viral persistence and 
demyelinating disease. By interfering with cytolytic T cell 
function, IL-17 blocks vigorous and effi   cient antiviral immu-
nity, thereby permitting sustained viral infection. This IL-
17  –  mediated feedback loop during viral infection favors viral 
escape from powerful antiviral eff  ector T cells. These proper-
ties of Th17 cells represent a previously unknown mechanism 
of viral persistence leading to the pathogenesis of virus-induced 
chronic diseases. 
  Our data show that TMEV-infected DCs promote the 
development of Th17 cells in vitro (  Fig. 1  ). These results 
strongly suggest that virus infection harnesses the ability of 
DCs to polarize CD4  +   T cells toward Th17 cells. In particu-
lar, IL-6 produced by DCs after viral infection appears to 
steer this skewed Th17 cell development. It is interesting to 
note that higher levels of Th17 cells are found in TMEV-in-
fected SJL mice than in B6 mice (  Fig. 2  ). This diff  erence be-
tween resistant B6 and susceptible SJL mice may refl  ect the 
diff  erential level of Th17 cell generation induced by DCs 
(  Fig. 1, A vs. E  ; and Fig. S2). LPS treatment likely enhances 
virus-infected DCs to induce Th17 development to the 
To determine whether IL-17 inhibits cytotoxic function by 
blocking apoptosis of target cells during long-term cytolytic 
reactions, levels of apoptotic cells were analyzed (  Fig. 6 D  ). 
The results showed that target cells are completely protected 
from CD8  +   T cell  –  mediated apoptosis in the presence of IL-
17, whereas eff  ector CD8  +   T cells remain unaltered. We fur-
ther assessed the eff  ects of an inhibitor of Fas  –  FasL interaction 
using human Fas:Fc (Fas  –  IgG Fc fusion protein) on IL-17  –
  mediated inhibition of cytotoxic function to confi  rm the in-
volvement of the Fas-dependent pathway (  Fig. 6 E  ). The 
addition of Fas:Fc protein dramatically inhibited slow CD8  +   
T cell  –  mediated lysis in the absence of IL-17 but not in the 
presence of IL-17, strongly suggesting that IL-17 interferes 
with CD8  +   T cell cytotoxic function via blocking the Fas  –
  FasL pathway (  Fig. 6 E  ), consistent with the inhibition of 
anti-Fas antibody  –  induced apoptosis by IL-17 (Fig. S5). 
  We further examined whether IL-17 exerts a similar ef-
fect on CD4  +   T cell  –  mediated apoptosis, because MHC class 
II  –  restricted CD4  +   T cell  –  mediated killing of target cells 
during viral infection has been reported (  37, 38  ). We used 
the OT-II TCR transgenic system to address the eff  ects of 
IL-17 treatment on CD4  +   T cell  –  mediated killing of epitope 
peptide  –  loaded target B cells. Again, the presence of IL-17 
signifi  cantly (greater than twofold) inhibited the apoptosis of 
OVA  323-339    –  loaded B cells induced by cognate interactions 
with OT-II CD4  +   T cells (  Fig. 6 F  ). To further understand 
the underlying mechanisms for protection of immune target 
cells by IL-17, expression levels of prosurvival B cell lym-
phoma  –  xl (Bcl-xl) and Bcl-2 proteins in B cells, BM cells, 
and BMDCs were assessed after treatment with IL-17 (  Fig. 6 G  ). 
B cells and BM cells, but not BMDCs, displayed elevated ex-
pression of both Bcl-xl and Bcl-2 in response to IL-17 treat-
ment (  Fig. 6 G  ), suggesting that IL-17  –  induced up-regulation 
of prosurvival protein expression contributes to the protec-
tion of target cells from eff   ector T cell  –  mediated killing. 
Thus, IL-17 apparently inhibits antiviral cytotoxic T cell 
function in vitro by protecting target cells from eff  ector T 
cell  –  induced apoptosis. 
  Anti  –  IL-17 antibody  –  treated mice display enhanced 
antiviral cytotoxic T cell function in vivo 
  To correlate the above in vitro results of enhanced target cell 
survival by IL-17 treatment (  Fig. 6  ) with those in virus-in-
fected mice in vivo, we sought to examine whether adminis-
tration of anti  –  IL-17 antibody into virus-infected SJL mice 
reduces the number of virus-permissive cells in the target or-
gan (CNS) and enhances antiviral cytotoxic T cell function. 
8 d after infection, the proportion and number of CNS-infi  l-
trating macrophages were signifi  cantly lower in anti  –  IL-17 
antibody  –  treated mice than in isotype antibody  –  treated mice 
(  Fig. 7 A  ), suggesting that cellular infi  ltration is aff  ected by 
antibody treatment, as previously reported (  5  ).   In contrast, a 
similar proportion and number of CNS-resident microglia 
were observed in both anti  –  IL-17 and isotype antibody  –
  treated mice (  Fig. 7 A  ). Notably, the expression of prosur-
vival Bcl-xl and Bcl-2 proteins in both infi  ltrating macrophages 322 IL-17 PROMOTES VIRAL PERSISTENCE AND PATHOGENESIS   | Hou et al. 
    Figure 6.         IL-17 inhibits antiviral cytotoxic T cell function.   (A) Splenocytes from B6 mice at 8 d after infection were pretreated for 24 h or were 
simultaneously treated with IL-17 (IL-17 Pre or IL-17 Sim, respectively), and were then subjected to a   51  Cr-release assay using VP2  121-130  – loaded  EL-4  tar-
get cells. (B) Splenocytes (effector cells) from TMEV-infected B6 mice were co-cultured with naive B6 splenocytes (target cells) loaded with VP2  121-130  
for 24 h in the presence of IL-17 at an E/T ratio of 10:1. The numbers in the plots indicate the frequency of granzyme B  –   or IFN-    – positive  CD8 +   T  cells. 
(C) Splenocytes from naive B6 mice were loaded with VP2  121-130   or  OVA 323-339   peptides and labeled with a lower or higher concentration of CFSE, respectively, 
as target cells. The labeled target and effector cells were pretreated separately with IL-17 for 24 h and co-cultured or cultured together in the presence of 
IL-17F or IL-17 for an additional 60 h. The numbers in each histogram represent percentages of the lower (VP2  121-130  ) and higher (OVA  323-339 )  concentra-
tions of CFSE-labeled cells. The arrow shows the specifi  c killing of target cells. (D) Apoptosis levels of effector and target cells from the cultures in C at an 
E/T ratio of 10:1 were assessed after a 24-h incubation (percentages are shown). (E) Levels of target cell destruction in the presence of Fas:Fc were as-
sessed 60 h after co-culture with effector cells at an E/T ratio of 30:1 (percentages are shown). The arrows show virus-specifi  c killing. (F) Levels of anti-
gen-loaded B cell killing by activated CD4  +   T cells were determined. Peptide-loaded B cells were co-cultured in the presence of LPS and PBS or IL-17 at a JEM VOL. 206, February 16, 2009 
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before viral infection protects mice from disease development, 
whereas such immunization after viral infection exacerbates 
disease progression, suggesting that expansion of CD4  +   T cells 
after infection may be pathogenic (  45  ). Although the protec-
tive roles of Th1 and its hallmark cytokine, IFN-    , have been 
previously documented, the roles of Th17 and IL-17 in viral 
infection  –  induced infl   ammatory disease remain undefi  ned. 
This cell linage plays a critical role in the protection against 
extracellular bacterial or fungal infections (  2, 5  –  9  ). In contrast, 
virus-specifi  c Th17 cells are detectable during early HIV in-
fection (  17  ), suggesting that Th17 cells may be associated with 
viral replication. Interestingly, mice lacking both of the tran-
scription factors T-bet and eomesodermin develop high levels 
of IL-17  –  producing CD8  +   T cells; these mice develop a pro-
gressive infl  ammatory and wasting syndrome after lympho-
cytic choriomeningitis viral infection (  25  ). Our results clearly 
demonstrate that Th17 cells and their cytokine IL-17 play a 
critical role in the pathogenesis of TMEV-induced chronic 
demyelinating disease (  Fig. 4  ), similar to that shown with ex-
perimental autoimmune encephalomyelitis and perhaps also 
human multiple sclerosis (  4, 11  ). Therefore, it is most likely 
that the pathogenic function of infection-induced Th17 cells 
observed with the TMEV model system is also applicable to 
other persistent viral infections, although this has yet to be 
determined. Furthermore, our data indicate that the patho-
genic role of Th17 cells is not mouse strain specifi  c. Both ge-
netically resistant B6 mice in conjunction with LPS treatment 
and susceptible SJL mice induce elevated Th17 responses and 
chronic viral infection leading to the development of demye-
linating disease (  Figs. 3 and 4  ). In particular, demyelinating 
disease development in genetically resistant B6 mice in con-
junction with LPS treatment suggests that a cytokine milieu 
induced by opportunistic infections of bacterial agents promotes 
Th17 responses during viral infection, leading to viral persis-
tence and chronic infection  –  associated diseases. Such an en-
hanced development of pathogenic Th17 responses may result 
in clinical episodes in which the timing of infection strongly 
coincides with the exacerbation of severe clinical symptoms 
in human multiple sclerosis, as well as in acute disseminated 
encephalomyelitis (  46  –  49  ). 
  One intriguing fi  nding in this study is that IL-17 impairs 
antiviral cytotoxic CD8  +   T cell responses (  Figs. 6 and 7  ). This 
regulatory role of IL-17 on CD8  +   T cell function had not 
previously been identifi  ed. In our system, TMEV infection in 
susceptible mice promotes the generation of Th17 cells that 
compromise antiviral cytotoxic T cell function via IL-17 pro-
duction. Previous fi  ndings that IL-17 promotes tumor growth 
(  50, 51  ) may also refl  ect the inhibitory eff  ect of IL-17 on 
cytotoxic CD8  +   T function against target tumor cells. It is 
well established that cytotoxic CD8  +   T cells confer protective 
pathogenic threshold of Th17 response in resistant B6 mice 
(  Fig. 3  ), as shown in vitro (Fig. S2). This diff  erence in Th17 
cell levels in the CNS of virus-infected mice correlates with 
IL-6 levels produced both in the CNS of TMEV-infected 
mice (  39  ) and by in vitro  –  infected antigen-presenting cells, 
including DCs and microglia from susceptible SJL versus re-
sistant B6 mice (  30, 40  ). An elevated level of IL-6 appears to 
be necessary for this skewing of Th17 cell diff  erentiation by 
virus-infected DCs in vitro (  Fig. 1  ), as well as in virus-in-
fected mice (  Fig. 3  ). It is conceivable that the cellular sources 
of IL-6 during virus infection may also include many dif-
ferent CNS-resident cells such as microglia and astrocytes, 
which serve as major potential viral reservoirs, and infi  ltrating 
cells, including DCs and macrophages (  30, 40  –  42  ). More-
over, preferential expression of TGF-     was found in the 
CNS of TMEV-infected SJL mice but not in B6 mice (  39  ), 
suggesting that TGF-     may also participate in the develop-
ment of Th17 cells in the CNS, because the diff  erentiation of 
Th17 cells requires TGF-     (  6  –  8  ). Thus, innate infl  ammatory 
responses to TMEV infection in DCs and other antigen-pre-
senting cells would most likely aff  ect the development of 
Th17 cells, leading to a critical modulation of adaptive im-
mune responses involved in virus  –  host interactions. 
  In contrast to resistant B6 mice that display rapid viral 
clearance and the absence of demyelinating disease develop-
ment after TMEV infection, susceptible SJL mice exhibit 
chronic viral persistence and disease progression (  28, 29  ). Ac-
tive viral replication is a critical determinant for persistent in-
fection and the development of chronic demyelinating disease 
(  43  ). In addition, virally induced infl  ammatory  mediators 
may also contribute to this harmful process. Although IL-17 
does not directly enhance TMEV infection/replication in 
permissive cells, this cytokine signifi  cantly increases the pro-
duction of virus-induced infl  ammatory mediators such as IL-6, 
KC, and MCP-1 (  Fig. 5  ). This suggests that IL-17  –  mediated 
signals amplify virus-induced innate responses involved in 
CNS infl  ammation, which leads to chronic demyelination. 
Consistent with our fi  ndings, a recent report indicated that 
IL-17 synergistically enhances human rhinovirus-16  –  induced 
epithelial production of the infl  ammatory mediator IL-8, a 
human homologue for mouse KC protein (  44  ). 
  Previously, the pathogenic role of CD4  +   T cells had been 
proposed based on delayed disease development after treat-
ment with anti  –  MHC class II antibody (  28, 29  ). The protec-
tive role of CD4  +   T cells has also been noted, as virus-infected 
CD4 or MHC class II KO mice succumb to TMEV-induced 
demyelinating diseases. However, these studies are diffi   cult to 
interpret partly because of the lack of protective Th1 as well 
as reduced CD8  +   T cells in the absence of CD4  +   T cell help. 
It is interesting to note that immunization with CD4 epitope 
1:5 ratio for 24 h with effector OT-II T cells that were preactivated with anti-CD3/CD28 antibodies. The numbers in each plot indicate the frequency of 
Annexin V  +   B220 +   B cells. (G) Intracellular expression levels of Bcl-xl and Bcl-2 proteins in LPS-stimulated B cells, BM cells, and BMDCs from naive B6 
mice were assessed after a 24-h incubation with PBS (shaded histogram) or IL-17 (open histogram). Relative median fl  uorescence intensity differences 
between the IL-17 and the PBS group are illustrated on the fl  ow histograms. Data are representative of four independent experiments.     
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sibly through the up-regulation of their prosurvival proteins 
(  Fig. 6  ). Because an IL-17 receptor  –  like gene has recently 
been identifi  ed as a novel antiapoptotic gene ( 57  ), it is conceiv-
able that the IL-17 receptor may have such an antiapoptotic 
property. Furthermore, Th17 cytokines other than IL-17 may 
be able to modulate protective antiviral T cell responses. For 
example, IL-21, an essential cytokine for the induction and 
maintenance of Th17 cells, has the potential to suppress the 
immunity to viral infection (  52  ) by secreting antiviral cyto-
kines or inducing the cytolysis of infected cells via the granule 
exocytosis and/or Fas  –  FasL pathway (  53  –  55  ). In addition, 
similar cytolysis of virus-infected cells is observed by CD4  +   T 
cells in an MHC class II  –  restricted manner during virus infec-
tion (  37, 38, 56  ). Our results indicate that IL-17 interferes 
with the Fas  –  FasL pathway of cytotoxic eff  ector CD4  +   and 
CD8  +   T cells by protecting target cells against apoptosis, pos-
    Figure 7.         Treatment of virus-infected mice with anti  –  IL-17 antibody elevates antiviral cytotoxic T cell function.   (A) Flow cytometry of CNS-
infi  ltrating cells from SJL mice treated with isotype or anti  –  IL-17 antibody at 8 d after infection (percentages are shown). The bar graph represents num-
bers of CNS-infi  ltrating CD45  hi CD11b +   macrophages and resident CD45  int CD11b +   microglia. ***, P   <   0.001 for anti  –  IL-17 versus isotype antibody  –  treated 
groups. (B and C) Intracellular expression of Bcl-xl and Bcl-2 in CNS macrophages and microglia (B) and CNS-infi  ltrating CD4  +   and  CD8 +   T cells (C) iso-
lated from SJL mice treated with isotype or anti  –  IL-17 antibody. Shaded and open histograms represent cells stained with isotype control and anti-Bcl 
antibodies, respectively. The number in each histogram shows the relative median fl  uorescence intensity difference between cells stained with anti-Bcl 
antibody and isotope control antibody. (D) Intracellular cytokine production by CNS-infi  ltrating cells from isotype or anti  –  IL-17 antibody  –  treated SJL mice 
was determined. The number in each plot indicates the frequency of IFN-    – producing  CD8 +   T cells. The bar graph represents numbers of IFN-    – produc-
ing viral epitope  –  specifi  c CD8  +   T cells. *, P   <   0.05, anti  –  IL-17 versus isotope antibody  –  treated groups. Data in A  –  D represent pooled CNS cells from three 
mice per group and are representative samples of three separate experiments (means   ±   SD are shown in A and D). (E) Enhanced lysis of dominant epitope 
VP3  159-166    –   and subdominant epitope VP3  173-181    –  loaded target cells in TMEV-infected SJL mice treated with anti  –  IL-17 antibody. SJL mice were treated 
with either isotype (  n   = 3) or anti  –  IL-17 (  n   = 3) antibody at days 0 and 7 relative to TMEV infection. At 8 d after infection, in vivo lysis activity was evalu-
ated in virus- and mock-infected mice (  n   = 3) that received the target cell injection. The numbers in each histogram show the percentages of CFSE-
  labeled virus epitope  –  loaded (lower fl  uorescence intensity) and OVA  323-339  – loaded  (higher  fl  uorescence intensity) target cells, respectively. The arrows 
represent the virus epitope  –  loaded target cells. One representative mouse from three mice per group is shown. The pattern of every mouse in each group 
was very consistent. These experiments were repeated once with three additional mice.     JEM VOL. 206, February 16, 2009 
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stained with mouse anti  –  TMEV 8C mAb (  65  ) followed by FITC-conju-
gated goat anti  –  mouse secondary antibody (Invitrogen). BMDCs were 
further stained with anti-CD11c  –  allophycocyanin (APC; BD). Levels of 
infectious virus in culture supernatants were determined with a standard 
plaque assay, as previously described (  30  ). The cytokines in culture superna-
tants were analyzed using ELISA kits for IL-6, IL-12p40, IL-12p70, and 
MCP-1 (OptEIA; BD); for IL-23 (eBioscience); and for KC (R  &  D Sys-
tems). For the cell death assay, adult B6 BM cells from a 2-d culture with 
GM-CSF, BMDCs from a 5-d culture, and neonatal astrocytes were infected 
for 24 h with TMEV (multiplicity of infection [MOI] of 10) in the presence 
or absence of 100 ng/ml IL-17 (PeproTech), and were then stained with 
APC-conjugated Annexin V (Invitrogen). 
  Isolation of CNS-infi   ltrated leukocytes and assessment of virus 
antigen-specifi  c  responses.     CNS-infi  ltrating leukocytes were isolated 
from TMEV-infected mice, as previously described (  30  ). Isolated CNS-infi  l-
trating leukocytes were restimulated with diff  erent doses of UV-TMEV for 
48 h. Splenocytes from virus-infected mice were cultured in the presence 
of 1   μ  g/ml UV-TMEV, 2   μ  M of mixed CD4 epitopes (VP4  25-38   and 
VP2  206-220  ), and 2   μ  M of mixed CD8 epitopes (VP2  121-130  , VP3  110-120  , and 
VP2  165-173  ), as previously described (  66  ). All peptides were synthesized by 
GeneMed Synthesis Inc. and used as previously described (  67  ). IFN-     and 
IL-17 levels in culture supernatants were assessed using ELISA kits (from 
BD [OptEIA] and R  &  D Systems, respectively). 
  Measurement of viral persistence in the CNS.     Brains and spinal cords 
were isolated from TMEV-infected mice after cardiac perfusion with Hank  ’  s 
buff  ered salt solution. A standard plaque assay was performed using tissue 
homogenates, as previously described (  30  ). 
  Intracellular staining and fl  ow cytometry.     For assessment of cytokine 
production by OT-II transgenic T cells, CD4  +   T cells were isolated from 
OT-II mice by positive immunomagnetic cell sorting (Miltenyi Biotec), 
primed with mock or TMEV-infected B6 BMDCs in the presence of 
OVA  323-339   for 4 d with or without IL-6 (both from PeproTech), or anti  –
  mouse IL-6 antibody (Invitrogen). These cultures were restimulated with 
50 ng/ml PMA and 1   μ  g/ml ionomycin (Sigma-Aldrich) for 6 h and were 
stained with anti  –  IFN-      –  APC, anti  –  IL-17  –  PE, and anti-CD4  –  FITC (all 
from BD). In some experiments, BMDCs were left unfi  xed or fi  xed with 
0.1% paraformaldehyde, as previously described (  30  ). To determine the 
level of IL-17 production by the whole CNS cells, CNS-infi  ltrating leuko-
cytes from TMEV-infected SJL and B6 mice at 8 d after infection were 
cultured with PMA plus ionomycin for 6 h and analyzed by fl  ow cytome-
try. Levels of virus-specifi  c CNS-infi  ltrating CD8  +   T cells were assessed by 
fl  ow cytometry after intracellular staining of IFN-     after stimulating CNS 
mononuclear cells for 6 h with dominant epitope VP3  159-166   or subdomi-
nant epitope VP3  173-181  . All antibodies used in fl  ow cytometry for cellular 
markers were purchased from BD. To analyze the expression of prosurvival 
proteins, splenic B cells were isolated by using anti-CD19 MicroBeads 
(Miltenyi Biotec). B cells stimulated with 10   μ  g/ml LPS, BM cells, and 
BMDCs were treated for 24 h with or without 100 ng/ml IL-17. These 
cells were then stained with anti  –  mouse Bcl-xl  –  FITC (Santa Cruz Bio-
technology, Inc.) or anti  –  mouse Bcl-2  –  FITC (eBioscience) and analyzed 
using fl  ow cytometry. To determine expression levels of prosurvival pro-
teins in vivo, CNS-infi  ltrating cells were isolated from TMEV-infected SJL 
mice treated with anti  –  IL-17 antibody at days 0 and 7 relative to viral in-
fection. These cells were stained with anti  –  mouse CD45-APC and anti  –
  mouse CD11b-PE (both from BD) for antigen-presenting cells, and 
anti  –  mouse CD4-APC or anti  –  mouse CD8-APC for T cells. All cells were 
further stained with anti  –  mouse Bcl-xl  –  FITC or anti  –  mouse Bcl-2  –  FITC 
and analyzed using fl  ow cytometry. 
  Cytokine production assays.     To assess cytokine production by VP2-
TCR transgenic T cells, naive CD4  +   T cells (CD4  +  CD25       CD44  low  ) sorted 
using a MoFlo (Dako) were co-cultured for 4 d with BMDCs pulsed with 
production of IFN-     by T lymphocytes and to drive cytotoxic 
CD8  +   T cells to apoptosis (  58  –  61  ). In addition, a TMEV sus-
ceptibility locus,   Tmevp3  , coincides with the IL-22 gene, which 
encodes IL-22, a Th17 cytokine (  62  ), suggesting a potential 
role of this T cell population in the development of demye-
linating disease. More studies with these cytokines would be 
helpful in clarifying the role of Th17 cells in the establishment 
of viral persistence and the consequent pathogenesis of virus-
induced chronic infl  ammatory diseases. 
  In summary, viral infection in antigen-presenting cells in 
vitro as well as in susceptible mice in vivo induces elevated 
IL-6 production that subsequently promotes the development 
of pathogenic Th17 cells. Th17 cells and their cytokine IL-17 
are potent promoters of viral persistence and the development 
of virally induced chronic infl  ammatory demyelinating dis-
ease. IL-17 inhibits virus-induced cell apoptosis; this protec-
tion of virus-infected cells serves as a powerful means for viral 
evasion of the immune system. The inhibition of apoptosis 
prolongs the life of infected cells on the one hand, and desen-
sitizes killing by cytotoxic T cells on the other, resulting in 
enhanced viral replication and persistence. The virus  –  host in-
teraction via Th17 cells and/or their cytokine IL-17 results 
in the establishment of persistent viral infection and harmful 
immune responses, leading to the pathogenesis of TMEV-
  induced demyelinating disease. Conversely, interference with 
this interaction by neutralizing IL-17 activity reduces lym-
phocyte infi  ltration to the CNS and inhibits disease develop-
ment. This particular interaction may also potentially operate 
in other chronic diseases associated with a variety of viral in-
fections and could be a target for therapeutic intervention. 
  MATERIALS AND METHODS 
  Mice.     Female SJL/J (SJL) and C57BL/6 (B6) mice were purchased from 
Harlan Sprague Dawley. IL-6 KO (IL-6      /     ) mice on a B6 background 
were obtained from the Jackson Laboratory. 6  –  8-wk-old mice were main-
tained and used according to the protocols approved by the Northwestern 
University Animal Care and Use Committee. TCR transgenic mice that 
recognize TMEV capsid protein peptide VP2  74-86   were generated with the 
genomic DNA of a T cell clone derived from the spinal cords of TMEV-
infected SJL mice (  63  ) by the Transgenic Core Facility at Northwestern 
University. Transgenic founder mice were backcrossed to SJL mice at least 
14 generations. 
  TMEV-induced demyelinating diseases.     Mice were intracerebrally 
infected with 30   μ  l (10  6   PFU) of the BeAn strain of TMEV, and clinical 
symptoms of disease were assessed weekly, as previously described (  30  ). 
For LPS treatment, B6 or IL-6 KO mice were intraperitoneally injected 
with LPS (20   μ  g/100   μ  l per mouse;   Escherichia coli   0111:B4; Sigma-
Aldrich) at days 0 and 5 relative to viral infection. For neutralization of 
IL-17 in vivo, mice were intraperitoneally injected with 100   μ  g anti  –  mouse 
IL-17A antibody (clone eBioMM17F3; eBioscience) in 200   μ  l at days 0, 7, 
and 14 relative to viral infection. 
  BMDCs, primary astrocyte cultures, and viral infection/replication 
assay.     BMDCs were generated in the presence of GM-CSF for 5 d, as pre-
viously described (  30, 64  ). Primary astrocytes were generated from 1  –  3-d-
old B6 neonates by diff  erential shaking, as previously described (  42  ). Virus 
infection/replication assays were performed 24 h after viral infection, as pre-
viously described (  30  ). Cells were subsequently fi  xed, permeabilized (perm/
fi  x solution; BD), blocked with 1% normal goat serum (Invitrogen), and 326 IL-17 PROMOTES VIRAL PERSISTENCE AND PATHOGENESIS   | Hou et al. 
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  Online supplemental material.     Fig. S1 shows the enhanced Th17 devel-
opment during persistent viral infection. Fig. S2 demonstrates the elevated 
diff  erentiation of Th17 cells induced by virus-infected DCs in the presence 
of LPS. Fig. S3 shows the cytokine production by CNS-infi  ltrating CD8  +   T 
cells after TMEV infection in B6 mice treated with anti  –  IL-17 antibodies. 
Fig. S4 compares the histopathology and viral persistence levels between mice 
treated with anti –  IL-17 and control antibodies. Fig. S5 presents the expression 
of IL-17R on BM cells and the range of IL-17  –  induced protection against 
apoptosis triggered by various treatments. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20082030/DC1. JEM VOL. 206, February 16, 2009 
ARTICLE
327
        39  .   Chang  ,   J.R.  ,   E.     Zaczynska  ,   C.D.     Katsetos  ,   C.D.     Platsoucas  , and   E.L.   
  Oleszak  .   2000  .   Diff  erential expression of TGF-beta, IL-2, and other 
cytokines in the CNS of Theiler  ’  s murine encephalomyelitis virus-in-
fected susceptible and resistant strains of mice.       Virology      .     278  :  346    –    360  .    
        40  .   Jin  ,   Y.H.  ,   M.     Mohindru  ,   M.H.     Kang  ,   A.C.     Fuller  ,   B.     Kang  ,   D.     Gallo  , 
and   B.S.     Kim  .   2007  .   Diff  erential virus replication, cytokine production, 
and antigen-presenting function by microglia from susceptible and re-
sistant mice infected with Theiler  ’  s virus.       J. Virol.       81  :  11690    –    11702  .    
        41  .   Kang  ,   M.H.  ,   E.Y.     So  ,   H.     Park  , and   B.S.     Kim  .   2008  .   Replication of 
Theiler  ’  s virus requires NF-kappaB-activation: higher viral replication 
and spreading in astrocytes from susceptible mice.       Glia      .     56  :  942    –    953  .    
        42  .   So  ,   E.Y.  ,   M.H.     Kang  , and   B.S.     Kim  .   2006  .   Induction of chemokine and 
cytokine genes in astrocytes following infection with Theiler  ’  s murine 
encephalomyelitis virus is mediated by the Toll-like receptor 3.       Glia      .   
  53  :  858    –    867  .    
        43  .   Trottier  ,   M.  ,   B.P.     Schlitt  ,   A.Y.     Kung  , and   H.L.     Lipton  .   2004  .   Transition 
from acute to persistent Theiler  ’  s virus infection requires active viral 
replication that drives proinfl  ammatory cytokine expression and chronic 
demyelinating disease.       J. Virol.       78  :  12480    –    12488  .    
        44  .   Wiehler  ,   S.  , and   D.     Proud  .   2007  .   Interleukin-17A modulates hu-
man airway epithelial responses to human rhinovirus infection.       Am. J. 
Physiol. Lung Cell. Mol. Physiol.       293  :  L505    –    L515  .    
        45  .   Mohindru  ,   M.  ,   B.     Kang  , and   B.S.     Kim  .   2006  .   Initial capsid-specifi  c 
CD4(+) T cell responses protect against Theiler ’  s murine encephalomyeli-
tisvirus-induced demyelinating disease.       Eur. J. Immunol.       36  :  2106    –    2115  .    
        46  .   Buljevac  ,   D.  ,   H.Z.     Flach  ,   W.C.     Hop  ,   D.     Hijdra  ,   J.D.     Laman  ,   H.F.   
  Savelkoul  ,   F.G.     van Der Meche  ,   P.A.     van Doorn  , and   R.Q.     Hintzen  . 
  2002  .   Prospective study on the relationship between infections and 
multiple sclerosis exacerbations.       Brain      .     125  :  952    –    960  .    
        47  .   Correale  ,   J.  ,   M.     Fiol  , and   W.     Gilmore  .   2006  .   The risk of relapses in 
multiple sclerosis during systemic infections.       Neurology      .     67  :  652    –    659  .    
        48  .   St  ü  ve  ,  O.  , and  S.S.    Zamvil  .  1999  .  Pathogenesis, diagnosis, and treatment of 
acute disseminated encephalomyelitis.       Curr. Opin. Neurol.       12  :  395    –    401  .    
        49  .   Young  ,   N.P.  ,   B.G.     Weinshenker  , and   C.F.     Lucchinetti  .   2008  .   Acute 
disseminated encephalomyelitis: current understanding and controversies.   
    Semin. Neurol.       28  :  84    –    94  .    
        50  .   Numasaki  ,   M.  ,   J.-i.     Fukushi  ,   M.     Ono  ,   S.K.     Narula  ,   P.J.     Zavodny  ,   T.   
  Kudo  ,   P.D.     Robbins  ,   H.     Tahara  , and   M.T.     Lotze  .   2003  .   Interleukin-17 
promotes angiogenesis and tumor growth.       Blood      .     101  :  2620    –    2627  .    
        51  .   Numasaki  ,   M.  ,   M.     Watanabe  ,   T.     Suzuki  ,   H.     Takahashi  ,   A.     Nakamura  ,   F.   
  McAllister  ,   T.     Hishinuma  ,   J.     Goto  ,   M.T.     Lotze  ,   J.K.     Kolls  , and   H.     Sasaki  . 
  2005  .   IL-17 enhances the net angiogenic activity and in vivo growth of 
human non-small cell lung cancer in SCID mice through promoting 
CXCR-2-dependent angiogenesis.       J. Immunol.       175  :  6177    –    6189  .   
        52  .   Wong  ,   P.  , and   E.G.     Pamer  .   2003  .   CD8 T cell responses to infectious 
pathogens.       Annu. Rev. Immunol.       21  :  29    –    70  .    
        53  .   Kagi  ,   D.  ,   F.     Vignaux  ,   B.     Ledermann  ,   K.     Burki  ,   V.     Depraetere  ,   S.   
  Nagata  ,   H.     Hengartner  , and   P.     Golstein  .   1994  .   Fas and perforin path-
ways as major mechanisms of T cell-mediated cytotoxicity.       Science      .   
  265  :  528    –    530  .    
        54  .   Lowin  ,   B.  ,   M.     Hahne  ,   C.     Mattmann  , and   J.     Tschopp  .   1994  .   Cytolytic 
T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.   
    Nature      .     370  :  650    –    652  .    
        55  .   Harty  ,   J.T.  ,   A.R.     Tvinnereim  , and   D.W.     White  .   2000  .   CD8+ T cell 
eff  ector mechanisms in resistance to infection.       Annu. Rev. Immunol.     
  18  :  275    –    308  .    
        56  .   van de Berg  ,   P.J.  ,   E.M.     van Leeuwen  ,   I.J.     Ten Berge  , and   R.     van 
Lier  .   2008  .   Cytotoxic human CD4(+) T cells.       Curr. Opin. Immunol.     
  20  :  339    –    343  .    
        57  .   You  ,   Z.  ,   X.-B.     Shi  ,   G.     DuRaine  ,   D.     Haudenschild  ,   C.G.     Tepper  ,   S.H.   
  Lo  ,   R.     Gandour-Edwards  ,   R.W.     de Vere White  , and   A.H.     Reddi  . 
  2006  .   Interleukin-17 receptor-like gene is a novel antiapoptotic gene 
highly expressed in androgen-independent prostate cancer.       Cancer Res.     
  66  :  175    –    183  .    
        58  .   Palmer  ,   M.T.  , and   C.T.     Weaver  .   2007  .   Immunology: narcissistic helpers.   
    Nature      .     448  :  416    –    418  .    
        59  .   Nurieva  ,   R.  ,   X.O.     Yang  ,   G.     Martinez  ,   Y.     Zhang  ,   A.D.     Panopoulos  ,   L.   
  Ma  ,   K.     Schluns  ,   Q.     Tian  ,   S.S.     Watowich  ,   A.M.     Jetten  , and   C.     Dong  .   2007  . 
        19  .   Hashimoto  ,   K.  ,   J.E.     Durbin  ,   W.     Zhou  ,   R.D.     Collins  ,   S.B.     Ho  ,   J.K.   
  Kolls  ,   P.J.     Dubin  ,   J.R.     Sheller  ,   K.     Goleniewska  ,   J.F.     O  ’  Neal  ,   et al  .   2005  . 
  Respiratory syncytial virus infection in the absence of STAT 1 results 
in airway dysfunction, airway mucus, and augmented IL-17 levels.     
J. Allergy Clin. Immunol.       116  :  550    –    557  .    
        20  .   Doherty  ,   P.C.  ,   W.     Allan  ,   M.     Eichelberger  , and   S.R.     Carding  .   1992  . 
  Roles of alpha beta and gamma delta T cell subsets in viral immunity.   
    Annu. Rev. Immunol.       10  :  123    –    151  .   
        21  .   Raff  atellu  ,   M.  ,   R.L.     Santos  ,   D.E.     Verhoeven  ,   M.D.     George  ,   R.P.   
  Wilson  ,   S.E.     Winter  ,   I.     Godinez  ,   S.     Sankaran  ,   T.A.     Paixao  ,   M.A.   
  Gordon  ,   et al  .   2008  .   Simian immunodefi  ciency virus-induced mucosal 
interleukin-17 defi  ciency promotes   Salmonella   dissemination from the 
gut.       Nat. Med.       14  :  421    –    428  .    
        22  .   Guo  ,   B.  ,   E.Y.     Chang  , and   G.     Cheng  .   2008  .   The type I IFN induction 
pathway constrains Th17-mediated autoimmune infl  ammation in mice.   
    J. Clin. Invest.       118  :  1680    –    1690  .    
      23  .   Shinohara  ,  M.L.  ,   J.H.     Kim  ,   V.A.     Garcia  , and   H.     Cantor  .  2008  .   Engagement 
of the type I interferon receptor on dendritic cells inhibits T helper 17 cell 
development: role of intracellular osteopontin.       Immunity      .     29  :  68    –    78  .    
        24  .   Sen  ,   G.C.     2001  .   Viruses and interferons.       Annu. Rev. Microbiol.       55  :
  255    –    281  .    
        25  .   Intlekofer  ,   A.M.  ,   A.     Banerjee  ,   N.     Takemoto  ,   S.M.     Gordon  ,   C.S.   
  Dejong  ,   H.     Shin  ,   C.A.     Hunter  ,   E.J.     Wherry  ,   T.     Lindsten  , and   S.L.   
  Reiner  .   2008  .   Anomalous type 17 response to viral infection by CD8+ 
T cells lacking T-bet and eomesodermin.       Science      .     321  :  408    –    411  .    
        26  .   Stumhofer  ,   J.S.  ,   A.     Laurence  ,   E.H.     Wilson  ,   E.     Huang  ,   C.M.     Tato  ,   L.M.   
  Johnson  ,   A.V.     Villarino  ,   Q.     Huang  ,   A.     Yoshimura  ,   D.     Sehy  ,   et al  .   2006  . 
  Interleukin 27 negatively regulates the development of interleukin 17-
producing T helper cells during chronic infl  ammation of the central 
nervous system.       Nat. Immunol.       7  :  937    –    945  .    
        27  .   Pene  ,   J.  ,   S.     Chevalier  ,   L.     Preisser  ,   E.     Venereau  ,   M.H.     Guilleux  ,   S.   
  Ghannam  ,   J.P.     Moles  ,   Y.     Danger  ,   E.     Ravon  ,   S.     Lesaux  ,   et al  .   2008  . 
  Chronically infl  amed human tissues are infi  ltrated by highly diff  erenti-
ated Th17 lymphocytes.       J. Immunol.       180  :  7423    –    7430  .   
        28  .   Dal Canto  ,   M.C.  ,   B.S.     Kim  ,   S.D.     Miller  , and   R.W.     Melvold  .   1996  . 
  Theiler  ’  s murine encephalomyelitis virus (TMEV)-induced demyelin-
ation: a model for human multiple sclerosis.       Methods      .     10  :  453    –    461  .    
        29  .   Brahic  ,   M.  ,   J.F.     Bureau  , and   T.     Michiels  .   2005  .   The genetics of the 
persistent infection and demyelinating disease caused by Theiler  ’  s virus.   
    Annu. Rev. Microbiol.       59  :  279    –    298  .    
        30  .   Hou  ,   W.  ,   E.Y.     So  , and   B.S.     Kim  .   2007  .   Role of dendritic cells in diff  er-
ential susceptibility to viral demyelinating disease.       PLoS Pathog.       3  :  e124  .     
        31  .   Whitton  ,   J.L.  ,   C.T.     Cornell  , and   R.     Feuer  .   2005  .   Host and virus deter-
minants of picornavirus pathogenesis and tropism.       Nat. Rev. Microbiol.     
  3  :  765    –    776  .    
        32  .   Pullen  ,   L.C.  ,   S.H.     Park  ,   S.D.     Miller  ,   M.C.     Dal Canto  , and   B.S.   
  Kim  .   1995  .   Treatment with bacterial LPS renders genetically resistant 
C57BL/6 mice susceptible to Theiler  ’  s virus-induced demyelinating 
disease.       J. Immunol.       155  :  4497    –    4503  .   
        33  .   Kroenke  ,   M.A.  ,   T.J.     Carlson  ,   A.V.     Andjelkovic  , and   B.M.     Segal  .   2008  . 
  IL-12  –   and IL-23  –  modulated T cells induce distinct types of EAE based 
on histology, CNS chemokine profi  le, and response to cytokine inhibi-
tion.       J. Exp. Med.       205  :  1535    –    1541  .    
        34  .   Son  ,   K.N.  ,   R.P.     Becker  ,   P.     Kallio  , and   H.L.     Lipton  .   2008  .   Theiler  ’  s 
virus-induced intrinsic apoptosis in M1-D macrophages is Bax mediated 
and restricts virus infectivity: a mechanism for persistence of a cytolytic 
virus.       J. Virol.       82  :  4502    –    4510  .    
        35  .   Kolls  ,   J.K.  , and   A.     Linden  .   2004  .   Interleukin-17 family members and 
infl  ammation.       Immunity      .     21  :  467    –    476  .    
        36  .   Lowin  ,   B.  ,   C.     Mattman  ,   M.     Hahne  , and   J.     Tschopp  .   1996  .   Comparison 
of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T 
lymphocytes.       Int. Immunol.       8  :  57    –    63  .    
        37  .   Jellison  ,   E.R.  ,   S.K.     Kim  , and   R.M.     Welsh  .   2005  .   Cutting edge: MHC 
class II-restricted killing in vivo during viral infection.       J. Immunol.     
  174  :  614    –    618  .   
        38  .   Palma  ,   J.P.  ,   R.L.     Yauch  ,   S.     Lang  , and   B.S.     Kim  .   1999  .   Potential role 
of CD4+ T cell-mediated apoptosis of activated astrocytes in Theiler  ’  s 
virus-induced demyelination.       J. Immunol.       162  :  6543    –    6551  .    328 IL-17 PROMOTES VIRAL PERSISTENCE AND PATHOGENESIS   | Hou et al. 
  Essential autocrine regulation by IL-21 in the generation of infl  amma-
tory T cells.       Nature      .     448  :  480    –    483  .    
        60  .   Korn  ,   T.  ,   E.     Bettelli  ,   W.     Gao  ,   A.     Awasthi  ,   A.     Jager  ,   T.B.     Strom  ,   M.   
  Oukka  , and   V.K.     Kuchroo  .   2007  .   IL-21 initiates an alternative pathway 
to induce proinfl  ammatory T(H)17 cells.       Nature      .     448  :  484    –    487  .    
        61  .   Barker  ,   B.R.  ,   J.G.     Parvani  ,   D.     Meyer  ,   A.S.     Hey  ,   K.     Skak  , and   N.L.   
  Letvin  .   2007  .   IL-21 induces apoptosis of antigen-specifi  c CD8+ T lym-
phocytes.       J. Immunol.       179  :  3596    –    3603  .   
        62  .   Levillayer  ,   F.  ,   M.     Mas  ,   F.     Levi-Acobas  ,   M.     Brahic  , and   J.F.     Bureau  . 
  2007  .   Interleukin 22 is a candidate gene for Tmevp3, a locus controlling 
Theiler  ’  s virus-induced neurological diseases.       Genetics      .     176  :  1835    –    1844  .     
        63  .   Kang  ,   J.A.  ,   M.     Mohindru  ,   B.S.     Kang  ,   S.H.     Park  , and   B.S.     Kim  .   2000  . 
  Clonal expansion of infi  ltrating T cells in the spinal cords of SJL/J mice 
infected with Theiler  ’  s virus.       J. Immunol.       165  :  583    –    590  .   
        64  .   Hou  ,   W.  ,   Y.     Wu  ,   S.     Sun  ,   M.     Shi  ,   Y.     Sun  ,   C.     Yang  ,   G.     Pei  ,   Y.     Gu  ,   C.   
  Zhong  , and   B.     Sun  .   2003  .   Pertussis toxin enhances Th1 responses by 
stimulation of dendritic cells.       J. Immunol.       170  :  1728    –    1736  .   
        65  .   Crane  ,   M.A.  ,   C.     Jue  ,   M.     Mitchell  ,   H.     Lipton  , and   B.S.     Kim  .   1990  . 
  Detection of restricted predominant epitopes of Theiler  ’  s murine en-
cephalomyelitis virus capsid proteins expressed in the lambda gt11 sys-
tem: diff  erential patterns of antibody reactivity among diff  erent mouse 
strains.       J. Neuroimmunol.       27  :  173    –    186  .    
        66  .   Myoung  ,   J.  ,   Y.     Il Bahk  ,   H.S.     Kang  ,   M.C.     Dal Canto  , and   B.S.     Kim  . 
  2008  .   Anti-capsid immunity level, not viral persistence level, correlates 
with the progression of Theiler  ’  s virus-induced demyelinating disease in 
viral P1-transgenic mice.       J. Virol.       82  :  5606    –    5617  .    
        67  .   Myoung  ,   J.  ,   W.     Hou  ,   B.     Kang  ,   M.A.     Lyman  ,   J.A.     Kang  , and   B.S.   
  Kim  .   2007  .   The immunodominant CD8+ T cell epitope region of 
Theiler  ’  s virus in resistant C57BL/6 mice is critical for anti-viral im-
mune responses, viral persistence, and binding to the host cells.       Virology      .   
  360  :  159    –    171  .    
        68  .   Ivanov  ,   I.I.  ,   B.S.     McKenzie  ,   L.     Zhou  ,   C.E.     Tadokoro  ,   A.     Lepelley  ,   J.J.   
  Lafaille  ,   D.J.     Cua  , and   D.R.     Littman  .   2006  .   The orphan nuclear recep-
tor RORgammat directs the diff  erentiation program of proinfl  amma-
tory IL-17+ T helper cells.       Cell      .     126  :  1121    –    1133  .    
        69  .   Zhao  ,   D.-M.  ,   A.M.     Thornton  ,   R.J.     DiPaolo  , and   E.M.     Shevach  .   2006  . 
  Activated CD4+CD25+ T cells selectively kill B lymphocytes.       Blood      .   
  107  :  3925    –    3932  .                      